EyePoint, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
EYPT$0.36+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference to SEC Filing | ||||
|---|---|---|---|---|
| ExhibitNo. | Exhibit Description | Form | SEC FilingDate | ExhibitNo. |
| 2.1# | Product Rights Agreement, dated May 17, 2023, by and between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc. | 8-K | 05/18/23 | 2.1 |
| 3.1 | Certificate of Incorporation of pSivida Corp. | 8-K12G3 | 06/19/08 | 3.1 |
| 3.2 | Certificate of Amendment of the Certificate of Incorporation of pSivida Corp. | 10-K | 09/13/17 | 3.2 |
| 3.3 | Certificate of Correction to Certificate of Amendment of the Certificate of Incorporation of pSivida Corp. | 8-K | 04/02/18 | 3.1 |
| 3.4 | Certificate of Amendment of Certificate of Incorporation, as amended, of EyePoint Pharmaceuticals, Inc. | 8-K | 06/27/18 | 3.1 |
| 3.5 | Certificate of Amendment of the Certificate of Incorporation, as amended, of EyePoint Pharmaceuticals, Inc. | 8-K | 06/23/20 | 3.1 |
| 3.6 | Certificate of Amendment of the Certificate of Incorporation, as amended, of EyePoint Pharmaceuticals, Inc. | 8-K | 12/08/20 | 3.1 |
| 3.7 | Certificate of Amendment to Certificate of Incorporation, as amended, of EyePoint, Inc. | 8-K | 12/08/25 | 3.1 |
| 3.8 | By-Laws of EyePoint Pharmaceuticals, Inc. | 10-K | 09/18/18 | 3.5 |
| 3.9 | Amendment No. 1 to the By-Laws of EyePoint Pharmaceuticals, Inc. | 8-K | 11/06/18 | 3.1 |
| 3.10 | Amendment No. 2 to the By-Laws of EyePoint, Inc. | 8-K | 12/08/25 | 3.2 |
| 4.1 | Form of Specimen Stock Certificate for Common Stock | 8-K12G3 | 06/19/08 | 4.1 |
| 4.2 | Form of Pre-Funded Warrant to Purchase Common Stock | 8-K | 11/19/21 | 4.1 |
| 4.3 | Form of Pre-Funded Warrant to Purchase Common Stock (2025) | 8-K | 10/17/25 | 4.1 |
| 10.1† | EyePoint, Inc. Amendment No 3. to 2023 Long-Term Incentive Plan | 8-K | 06/22/26 | 10.1 |
| 10.2# | Settlement Agreement, dated July 17, 2026, by and among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services and the Defense Health Agency, acting on behalf of the TRICARE Program, EyePoint, Inc., and the relator named therein, through their authorized representatives. | 8-K | 07/17/26 | 10.1 |
| 10.3# | Corporate Integrity Agreement, dated July 13, 2026, by and among the Office of Inspector General of the Department of Health and Human Services and EyePoint, Inc | 8-K | 07/17/26 | 10.2 |
| 10.4* | Sixth Amendment to Lease, dated February 13, 2026, between GRE Riverworks, LLC and EyePoint, Inc. | |||
| 31.1* | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |||
| 31.2* | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |||
| 32.1** | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|---|---|
| 32.2** | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document and included in Exhibit 101) |
Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.
† Indicates management contract or compensatory arrangement.
- Filed herewith
** Furnished herewith
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.